The Elixinol Global Ltd (ASX: EXL) share price will be on watch this morning after the global distributor of industrial hemp based dietary supplements announced the successful completion of its institutional placement.
What was announced?
According to the release, Elixinol Global has raised $50 million through the issue of approximately 12.8 million shares at $3.90 per share to institutional investors. This represents an 8.7% discount to its last close price.
Management advised that it intends to use the proceeds to fund its ongoing expansion initiatives, with a particular focus on growing its USA CBD business.
In addition to this, the company will use the proceeds to expand its production facilities in Colorado by an additional ~23,000 square feet to more than double the company’s current production capacity, undertake opportunistic strategic acquisitions, and enter joint ventures in select markets.
The company’s chief executive officer, Paul Benhaim, appeared to be very pleased with the successful placement and believes it has left Elixinol Global very well positioned for growth.
He said: “I acknowledge the strong support of new and existing institutional investors to accelerate the Company’s expansion in the US and globally. We are witnessing an unprecedented positive shift in consumer appetite for CBD and hemp derived products. Elixinol plans to double its current production capacity in the US. Further, by securing additional raw materials, the Company will be well positioned to accelerate the growth of Elixinol branded CBD products and strategic opportunities.”
Also in the news this morning in the cannabis industry is Althea Group Holdings Ltd (ASX: AGH). Earlier today it revealed that Agriculture Victoria has granted its wholly owned subsidiary, Althea Company, an Authority for Low-THC Cannabis (Hemp Cultivation Licence) for commercial purposes relating to non-therapeutic use.
And on Tuesday the MGC Pharmaceuticals Ltd (ASX: MXC) share price climbed higher after it confirmed material revenue generation from its non-pharmaceutical business units during the June quarter.
A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming. To the tune of an estimated $US22 billion.
Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.
Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.
AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.
Simply click below to learn more on how you can profit from the coming cannabis boom.
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.